---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-005562"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T20:53:51.424726+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Corcept reports Q4 revenue $103.1M, FY 2022 revenue $401.9M; guides 2023 revenue $430-450M

## Summary
- Q4 2022 revenue $103.1M vs $98.8M Q4 2021; FY revenue $401.9M vs $366.0M.
- FY 2022 diluted EPS $0.87 vs $0.89 in 2021; net income $101.4M vs $112.5M.
- Cash and investments $436.6M at Dec 31, 2022, up from $335.8M year-end 2021.
- NDA for relacorilant in Cushing's syndrome expected Q1 2024; GRACE enrollment closing.
- Phase 3 ROSELLA (ovarian cancer) and Phase 2 DAZALS (ALS) enrolling; miricorilant Phase 1b NASH data mid-2023.

## SEC filing metadata
- accession: 0001628280-23-005562
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000162828023005562/0001628280-23-005562-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000162828023005562/cort-20230228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-005562
- JSON: https://secwatch.observer/filing/0001628280-23-005562.json
- Plain text: https://secwatch.observer/filing/0001628280-23-005562.txt

## Key facts
- Earnings Releases
  CORCEPT THERAPEUTICS INC reported the quarter and year ended December 31, 2022 results: revenue $103.1 million, net income $16.6 million, EPS $0.14 per diluted common share. Guidance reaffirmed.
  - Period: the quarter and year ended December 31, 2022
  - Revenue: $103.1 million
  - Net income: $16.6 million
  - EPS: $0.14 per diluted common share
  - Guidance: reaffirmed
  - Result: reported results
  source text: Fourth quarter revenue of $103.1 million, compared to $98.8 million in fourth quarter 2021 • 2022 revenue of $401.9 million, compared to $366.0 million in 2021 • 2023 revenue guidance of $430 – $450 million • Fourth quarter diluted net income per common share of $0.14, compared to $0.26 in fourth quarter 2021 • 2022 diluted net income per common share of $0.87, compared to $0.89 in 2021 • Cash and investments of $436.6 million, compared to $335.8 million at December 31, 2021 Corcept’s fourth quarter 2022 revenue was $103.1 million, compared to $98.8 million in the fourth quarter of 2021. Revenue for the full year was $401.9 million, compared to $366.0 million in 2021. The company expects 2023 revenue of $430 – $450 million. Net income was $16.6 million in the fourth quarter of 2022, compared to $32.1 million in the fourth quarter of 2021. For the full year, it was $101.4 million compared to $112.5 million in 2021. Cash and investments of $436.6 million at December 31, 2022 compared to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1088856/000162828023005562/0001628280-23-005562-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.